Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mutaflor in Mild-to-Moderate Ulcerative Colitis
NCT04969679Phase 4Completed
- Sponsor
- Kangbuk Samsung Hospital
- Start
- Mar 2018
- Primary completion
- Jun 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 4 trial of escherichia coli nissle 1917 in ulcerative colitis (UC), sponsored by Kangbuk Samsung Hospital. Started Mar 2018; status: completed.
02
Drugs
escherichia coli nissle 1917
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04969679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04969679.